Item 7.01. Regulation FD Disclosure.

On January 9, 2023, Gamida Cell Ltd. (the "Company") posted an updated corporate presentation on the Company's website. To access the presentation, investors should visit the "Investors & Media" section of the Company's website at www.gamida-cell.com.

The information furnished under this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events.

In the fourth quarter of 2022, the Israeli Ministry of Health and the United States Food and Drug Administration (the "FDA") completed physical inspections of the Company's Kiryat Gat, Israel manufacturing facility. The Company will commercially manufacture omidubicel for sale in the United States at such facility if omidubicel is approved for marketing by the FDA.


                                       1

© Edgar Online, source Glimpses